Silicon-germanium heterojunction bipolar transistors can be used to construct low-noise cryogenic amplifiers. We present a dc-coupled differential amplifier capable of operating down to 10 K. In this temperature regime it has bandwidth of 15 MHz and noise temperature as low as 1.3 K. When operated at liquid nitrogen temperature of 77 K, the measured noise temperature is lower than 3 K. The amplifier is based on the commercially available transistors NESG3031 and operational amplifier OPA836 and is capable of standalone operation without any additional stages at room temperature.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1063/1.4729665 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lighting Up Dual-Aptamer-Based DNA Logic-Gated Series Lamp Probes with Specific Membrane Proteins for Sensitive and Accurate Cancer Cell Identification.
Anal Chem
January 2025
Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, Cixi Biomedical Research Institute, School of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou 325035, China.
Accurate identification of cancer cells under complex physiological environments holds great promise for noninvasive diagnosis and personalized medicine. Herein, we developed dual-aptamer-based DNA logic-gated series lamp probes (Apt-SLP) by coupling a DNA cell-classifier (DCC) with a self-powered signal-amplifier (SSA), enabling rapid and sensitive identification of cancer cells in a blood sample. DCC is endowed with two extended-aptamer based modules for recognizing the two cascade cell membrane receptors and serves as a DNA logic gate to pinpoint a particular and narrow subpopulation of cells from a larger population of similar cells.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital, Mölndal, Sweden.
Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).
Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.
Background: Distinct amyloid structures characterize specific proteinopathies, including tau and α-synuclein based neurodegenerative diseases. However, how protein seed co-occurrence and other pathologic features account for clinicopathological heterogeneity observed within and between proteinopathies is unclear. Here, we quantify α-synuclein and isoform-specific tau seeds across neurodegenerative diseases, including in Lewy body disease (LBD), AD neuropathologic change (ADNC), and 4R tauopathy cases to inform how co-occurring seeds may impact disease presentation and trajectory.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Mathematical, Computational, and Systems Biology, University of California, Irvine, Irvine, CA, USA.
Background: Faced with a rapidly aging population and the rising prevalence of Alzheimer's disease (AD) and related dementias, the field needs to urgently consider screening tools that utilize widely accessible data modalities. We have previously shown that lower-cost data, operationalized as data modalities accessible at primary care visits, can indeed accurately predict AD clinical diagnosis and that clustering these data can provide useful information. Here, we apply a similar approach to predicting histopathological status.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Oregon Health & Science University, Portland, OR, USA.
Background: Alzheimer's disease (AD) is the most common cause of dementia, and the fifth leading cause of death for those 65 and older. Brain changes in AD begin 10-20 years before symptoms appear, yet markers for early brain changes are lacking. We discovered and validated miRNAs in human cerebrospinal fluid (CSF) that differentiate AD from Controls.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!